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Abstract
Developing cancer therapeutics that radiosensitize in a tumor-selective man-
ner remains an ideal. We developed a novel means of radiosensitization, exploiting 
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) overexpression, and lowered catalase 
expression in solid human tumors using NQO1-bioactivatable drugs. Non-small cell 
lung (NSCLC), pancreatic (PDAC), prostate, and breast cancers overexpress NQO1. 
Ionizing radiation (IR) creates a spectrum of DNA lesions, including lethal DNA 
double-strand breaks (DSBs), and mutagenic but rarely lethal altered DNA bases and 
DNA single-strand breaks (SSBs). NQO1-bioactivatable drugs (e.g., β-lapachone and 
deoxynyboquiones) also promote abasic DNA lesions and SSBs. These hyperactivate 
poly (ADP-ribose) polymerase 1 (PARP1) and dramatically increase calcium release 
from the endoplasm reticulum (ER). Exposure of human cancer cells overexpressing 
NQO1 to NQO1-bioactivatable drugs immediately following IR, therefore, hyperac-
tivates PARP1 synergistically, which in turn depletes NAD+ and ATP, inhibiting DSB 
repair. Ultimately, this leads to cell death. Combining IR with NQO1-bioactivatable 
drugs allows for a reduction in drug dose. Similarly, a lower IR dose can be used in 
combination with the drug, reducing the effects of IR on normal tissue. The combi-
nation treatment is effective in preclinical animal models with NSCLC, prostate, and 
head and neck xenografts, indicating that clinical trials are warranted.
Keywords: NQO1 expression, PARP hyperactivation, abasic site synergy,  
NAD+/ATP losses, DSB repair inhibition, programmed necrosis
1. Introduction
For decades, radiobiologists and physician-scientists have collaborated to develop 
effective combination therapies with ionizing radiation and radiosensitizing agents 
to reduce the overall dose of radiation required in cancer therapy. This minimizes 
adverse side-effects observed in normal tissues and increases the efficacy of radiation 
in reducing tumor burden. Here, we discuss the pros and cons of radiosensitizing 
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agents used in the clinic in comparison with NAD(P)H quinone oxidoreductase-1 
(NQO1)-bioactivatable drugs. β-Lapachone (β-Lap) is a clinical chemotherapeutic 
agent discovered to be a potent DNA repair inhibitor in the late 1980s. It has since 
been shown to be bioactivated by NQO1, an enzyme elevated more than 20-fold in 
most solid human cancers, e.g., non-small cell lung, pancreas, prostate, head and 
neck, and breast cancers, and shows promise as a potent radiosensitizer.
2. Radiotherapy as a single agent
2.1 Initial use of ionizing radiation
The late 19th-century discovery of the X-ray by Wilhelm Roentgen led to 
diagnostic tools and therapies for diseases such as blood disorders and benign and 
malignant growths [1, 2]. Initially, radiation was delivered using unfocused beams, 
causing skin and blood malignancies in both patients and radiologists [1, 2]. Today, 
patients benefit from vast technological improvements, allowing for focused radia-
tion beams, which markedly increased patient survival. Current approaches include 
conformal radiation therapy, proton beam radiation therapy, stereotactic radiation 
therapy (using linear accelerators or gamma knife devices), and intraoperative 
therapy [3]. Despite improvements in targeting tumors and reducing normal tissue 
damage, high doses of radiation are still required for a curative effect. Some tumors 
can also be resistant to radiotherapy, including hypoxic tumors and dormant cancer 
cells that regrow when the optimal tumor microenvironment presents itself. Thus, 
methods to improve the safety and efficacy of ionizing radiation were initiated, 
including combination with chemotherapeutics or radiosensitizers.
2.2 Enhancing radiation therapy with radiosensitizers
Radiosensitizing agents are molecules that enhance the dose of ionizing radia-
tion delivered to a patient’s tumor. The optimal clinical radiosensitizer (a) lowers 
the required dose of ionizing radiation, (b) increases its antitumor effect, and (c) 
Radiosensitizer Tumor type Mechanism
Hyperbaric oxygen Brain tumors Oxygenation
Nicotinamide Glioblastoma Oxygenation
Metronidazole Cervical cancer Oxygenation
Mitomycin-C Breast cancer Kills hypoxic cells
5-fluorouracil (5FU) Gastrointestinal S-phase check points
Bromodeoxyuridine (BrDU) Breast Repair inhibition
Topo-inhibitors Breast, cervical DNA damage
NBTXR3 Solid tumors Direct
Nimoral Head and neck Modifies hypoxia
Trans sodium crocetinate Glioblastoma Oxygenation
NVX108 Glioblastoma Oxygenation
List of commonly used radiosensitizing methods/agents for combination with radiotherapy in various tumor types. 
The last four are emboldened to denote their current use in ongoing clinical trials.
Table 1. 
Clinical radiosensitizers.
3NQO1-Bioactivatable Therapeutics as Radiosensitizers for Cancer Treatment
DOI: http://dx.doi.org/10.5772/intechopen.90205
synergistically kills cancer cells. To date, no radiosensitizer has met these demands. 
Many radiosensitizers have been used clinically (Table 1, normal text) with limited 
success, or are currently in clinical trial (Table 1, bold text). These include suppres-
sors of radioprotectors (e.g., thiol) [4], molecules releasing cytotoxic substances 
when radiolyzed [5], thymine/cytidine analogs [6], oxygen mimic sensitizers [7], 
and DNA repair inhibitors [8].
3. β-Lapachone, a DNA repair inhibitor
3.1 Initial discovery of β-lapachone’s effect on DNA repair
In the late 1980s, our laboratory began searching for DNA repair modulators 
that synergize with ionizing radiation to kill cancer cells more effectively. The goal 
was to thwart cancer cells’ ability to repair IR damage, to avoid the survival of 
IR-resistant malignant cells that have undergone potentially lethal damage repair 
(PLDR). One of those compounds was (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-
b]pyran-5,6-dione), also known as β-lapachone [9].
We found that just four micromolar β-lapachone inhibited single-strand DNA 
break repair in cancer cells exposed to DNA-damaging agent methyl methane 
sulfonate [9, 10], killing 99% of cells at an exposure time 90–120 min [11]. 
Additionally, we found that combining β-lapachone with ionizing radiation in Hep2 
cells increased double-strand breaks and dramatically lowered the dose of radiation 
required for cell death, highlighting β-lapachone as a potent radiosensitizer [12].
In the 1990s and early 2000s, we conducted subtraction-hybridization screen-
ing to isolate X-ray inducible genes to investigate ionizing radiation resistance and 
found Xip3, also known as NQO1 [13]. Dicoumarol, an NQO1 inhibitor, specifi-
cally blocked β-lapachone’s toxicity, indicating that the radiosensitizer may be 
bioactivated by this enzyme. As NQO1 is specifically expressed in tumor cells, this 
indicated a promising use of β-lapachone as a cancer therapeutic with or without 
ionizing radiation.
4. Mechanism of action for NQO1-bioactivatable therapies
4.1 NQO1 vs. catalase ratio and specificity
NQO1 is a Phase II detoxification enzyme that reduces ROS levels in cancer cells. 
NQO1 converts quinones into stable intermediate hydroquinones that are exported 
out of the cell by conjugation [10]. Most solid cancers, including non-small cell lung 
and pancreatic cancers (>85%), prostate, colon, and breast cancers (60%) and head 
and neck cancers (40%) overexpress NQO1 5- to 200- fold above normal tissue. 
Corresponding levels of catalase in these cancers were strikingly reduced, impacting 
the ability of cancer cells to eliminate ROS [14]. Overexpression of NQO1 appears to 
stabilize HIF-1alpha and promotes metastasis [15].
Though NQO1 detoxifies most quinones through two-electron oxidoreduction, 
a few quinones undergo a rapid futile redox cycle response, generating an unstable 
intermediate hydroquinone that spontaneously reverts back to its original form 
using two oxygenation steps and creating two superoxides. Deoxynyboquiones 
(DNQ ), KP372 agents, and β-lapachone are three classes of NQO1-bioactivatable 
drugs currently known [16]. Recently, Napabucasin, an orphan drug in clinical 
trials for pancreatic and cervical cancer, has also been reported to be bioactivated 
by NQO1 [17]. Though mitomycin C and streptonigrin are metabolized by NQO1, 
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these agents can also be activated by other drug metabolizing enzymes [18]. Human 
cancer cells overexpressing NQO1 have been shown to be sensitive to NQO1-
bioactivatable drugs alone and in combination with PARP inhibitors, cisplatin, 
radiation, and NAMPT inhibitors both in cell culture and xenograft models [14, 19].
4.2 NQO1-dependent ROS formation and PARP hyperactivation
Cancer cells overexpressing NQO1 and exposed to NQO1-bioactivatable drugs, 
such as β-lapachone, DNQ or IB-DNQ , acquire extensive DNA lesions as evidenced 
by alkaline comet assays [11]. The unstable hydroquinone form of these NQO1 
bioactivatable drugs reacts with two oxygen molecules spontaneously to regenerate 
the original compound [20]. This futile redox cycle consumes ~60 moles of NADPH 
to generate ~120 moles of ROS in ~2 min for β-lapachone, leading to the generation 
of permeable hydrogen peroxide (H2O2). This diffuses into the nucleus and causes 
massive oxidative stress and SSBs [16]. Initial DNA damage is mainly through the 
formation of altered bases, SSBs, and apurinic/apyrimidinic (AP) sites generated 
through incorporation of 8-oxo-deoxyguanine [21]. Ultimately, damage caused by 
H2O2 results in extensive SSBs and DSBs. These lesions lead to PARP hyperactiva-
tion that can be prevented by BAPTA-AM (chelates Ca2+), PARP inhibitors, or the 
NQO1 inhibitor dicoumarol, in NQO1+ cells. In contrast, cells deficient in NQO1 
due to NQO1 polymorphisms, *2[C609T] or *3[C465T], are unaffected by exposure 
to NQO1-bioactivatable compounds [14], lacking the enzyme activity for redox 
cycling Hyperactivation of PARP rapidly degrades the increased NAD+ pools gener-
ated as a result of the oxidation of NADH in the futile cycle [11, 20, 22]. NAD+ loss 
is not seen in cells treated with PARP1 inhibitors; instead, cells exposed to PARP 
inhibitors in combination with NQO1-bioactivatable drugs undergo a synergistic 
apoptotic cell death response [14].
4.3  Calcium release, DNA damage and μ-Calpain-dependent programmed 
necrosis
One of the key components in the cell death response by NQO1-bioactivatable 
drugs is the release of calcium from the core endoplasmic reticulum (ER) 
stores, which is otherwise inert [11, 23]. This results in specific programmed 
necrosis referred to as NAD+ -Keresis. Pre-treatment, with the calcium chelator, 
BAPTA-AM, suppresses PARP hyperactivation and results in specific inhibition of 
NQO1-dependent cell death by NQO1-bioactivatable drugs. Extensive DNA dam-
age along with Ca2+ release from the ER results in the hyperactivation of PARP1 in 
NQO1+ cancer cells. PARP1 hyperactivation rapidly degrades the NAD+ and causes 
concomitant ATP losses within 30–40 min of drug treatment. μ-Calpain activation 
is observed upon treatment with NQO1-bioactivatable drugs within 8–24 h [16, 24]. 
The multitude of damage caused by treatment with these drugs overwhelms DNA 
repair machinery and depletes the cells of the energy resources, culminating in cell 
death [10, 11, 16, 20, 24–27].
4.4 NQO1-bioactivatable drugs lead to perturbations in metabolic pathways
Treatment with NQO1-bioactivatable drugs causes wide-scale metabolic changes 
in the cell, which can be attributed to cell death overwhelming the cellular machin-
ery. Altering key enzymes in NAD metabolism results in synergy with NQO1-
bioactivatable drugs. NAMPT is an important source of reducing equivalents for 
redox balance in cancer cells. Pretreatment with FK866, a NAMPT inhibitor, leads 
to accelerated cell death due to decrease in NAD+/NADH levels and reduced doses 
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of NQO1-bioactivatable drugs [28]. NAMPT knockdown has also been shown to 
sensitize cancer cells to ROS induction through ionizing radiation [29, 30].
4.5 Exploiting NQO1-bioactivatable drugs as radiosensitizers
Cancer cells, tissues, and organs subjected to ionizing radiation experience a wide 
spectrum of DNA lesions including SSBs, DSBs, AP sites and DNA-protein cross-
links. One unrepaired DSB is lethal to the cell [21, 31]. Hence, NQO1-bioactivatable 
drugs, when combined with IR (Figure 1), synergistically kill cancer cells due to 
the combined effect of DNA damage and PARP1 hyperactivation [21, 32]. Sublethal 
doses of NQO1 drugs and IR combine to release massive amounts of ROS due to 
Figure 1. 
Radiation sensitization by NQO1 bioactivatable drugs: sublethal doses of β-lapachone when bioactivated 
by NQO1 release massive amounts of ROS, resulting in synergy with IR and increased programmed necrosis. 
NQO1 bioactivatable drugs in combination with IR show tremendous synergy even at low doses. The combined 
effect of DNA damage and PARP hyperactivation provides more lethality to a cancer cell whereas NQO1 
provides the specificity. This leads to increased ROS, gH2AX formation, hyperactivation of PARP, massive 
NAD and ATP losses, prevention of DSB repair, perturbations in the metabolic pathways, and μ-Calpain-
mediated programmed necrosis known as NAD + -Keresis.
Figure 2. 
Sublethal doses of IR and β-lap in NQO1+ LNCaP cells cause PARP-1 hyper-activation and dramatic 
ATP loss: A, LNCaP cells expressing or lacking NQO1 were treated with IR + β-lap and monitored for PAR 
formation—UT, untreated control for IR; V, vehicle; DMSO only. B, Synergistic ATP loss was noted after 
IR + β-lap compared to single treatments alone. Results are means ± SE for experiments performed three times 
in duplicate. Student’s t-tests compared single to combined treatments. ***p < 0.001, **p < 0.01.
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their synergy, resulting in PARP hyperactivation, loss of nucleotides and increased 
programmed necrosis (Figures 2 and 3), beyond the capabilities of the single agents 
(IR or NQO1-bioactivatable drug) alone. Head and neck cancers, PDA and NSCLC 
Figure 4. 
β-Lap radiosensitizes subcutaneous A549-luc xenografts in athymic nude mice: A. subcutaneous A549-luc 
xenografts (400 mm3) were generated in athymic nude mice and then treated with or without IR (2 Gy) then 
immediately with or without β-lap (20 mg/kg) for 5 treatments every other day. Representative antitumor 
responses (at day 20 post-treatment) are demonstrated for β-lap alone, IR alone, and the IR + β-lap 
combination. B. Antitumor responses (tumor volumes, mm3) over time are shown for the treatments described 
in Figure 3A. C. Overall survival of animals treated as described in Figure 3A. D. PK values for plasma and 
subcutaneous vs. orthotopic A549-luc tumors in athymic nude mice. Note the significantly high levels of β-lap in 
orthotopic vs. subcutaneous A549 tumor tissue, whereas plasma levels were identical in both sets of mice.
Figure 3. 
β-Lap inhibits DNA double strand break repair: A. log-phase A549 NSCLC cells were treated with or without 
β-lap (6 μM) and cell extracts prepared at various times during treatment to detect PAR-PARP formation, 
γ-H2AX (pS139), pS1981 ATM, total ATM (t-ATM) and α-tubulin steady-state levels by Western blot. A549 
cells were also exposed or not to IR (8 Gy) and analyzed 1 h later. Mock, non-irradiated cells. DM, media 
alone. B. Graphical representation of data shown in Figure 2A. C. Representative images of A549 cells exposed 
or not to IR (2 Gy) alone, β-lap (3 μM, 2 h) alone, the combination [IR (2 Gy) + β-lap (3 μM, 2 h)], or the 
combination with DIC (50 μM, NQO1 inhibitor) and assessed for DSB breaks over time (0–120 min) using 
53BP1 as the surrogate marker (in red). Cells were also stained for nuclear DNA using DAPI (in blue). Scale 
bar = 10 μm. D. Graphical representation of data presented in Figure 2C; ****p < 0.0001.
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have been shown to be sensitive to nontoxic doses of β-lapachone when combined 
with IR [21, 32]. Using NQO1-bioactivatable drugs as radiosensitizers leads to 
increases in ROS, γH2AX formation, hyperactivation of PARP1, massive NAD+ 
and ATP losses, inhibition of DSB repair, perturbation in carbon flux pathways and 
μ-Calpain mediated programmed necrosis known as NAD + -Keresis. The cell death 
responses observed are independent of any oncogenic drivers [21, 31–33]. This lethal 
combination between radiation therapy and NQO1-bioactivatable drugs prolongs 
long-term survival and promotes enhanced tumor shrinkage at non-toxic doses of 
each agent (IR and Drug, Figure 4). Thus, combining NQO1-bioactivatable drugs 
with radiation therapy, should be a long-standing treatment modality for tumors 
overexpressing NQO1.
5. Discussion
5.1 Advantages of NQO1-bioactivatable drugs vs. other radiosensitizers
The major advantage of using NQO1-bioactivatable drugs as radiosensitizers 
is the tumor selectivity afforded by the drugs themselves. Synergy is afforded by 
a number of tumor-selective responses to the drugs. First, the dependence of the 
drugs on NQO1 levels is perfect for the specific treatment of various difficult-to-
treat human cancers, including non-small cell lung, pancreatic, breast, prostate, 
and head and neck cancers. Tumor selectivity requires approximately 100 units of 
enzyme activity, whereas lower levels of NQO1 results in mild metabolomic altera-
tions used for the treatment of metabolic syndromes [34]. Second, the minimum 
time of exposure of 30–120 min fits the pharmacokinetics of the drug. It should 
be noted that all studies thus far indicate that the drugs have to be available imme-
diately after or at the same time as exposure with IR. Pre-treatment prior to IR is 
ineffective. Third, synergy between NQO1-bioactivatable drugs and IR occurs due 
to PARP1 hyperactivation causing massive NAD+ and ATP loss, preventing repair 
of the DNA damage created by IR. NQO1-bioactivatable drugs are highly specific 
to tumors, causing little normal tissue toxicity, which is unaffected by IR treatment 
[14, 16, 20, 25, 31]. Preclinical in vivo data suggest that radiosensitization trials 
with NQO1-bioactivatable drugs are warranted for non-small cell lung, pancreatic, 
breast prostate, and head and neck cancers.
5.2 Future directions for NQO1-bioactivatable drugs
A clinical trial of radiation sensitization effects of the new drug, isobutylde-
oxynyboquione (IB-DNQ ), against non-small cell lung (NSCLC) and/or pancre-
atic adenocarcinomas (PDAC) is warranted. These cancers are almost uniformly 
NOQ1 over-expressive and they have routinely low levels of catalase [14]. We have 
developed CLIA assessments of NQO1 status and enzymatic levels for these stud-
ies. The pharmacokinetics of IB-DNQ in these cancers, particularly in NSCLC and 
PDAC cancers, is relatively short at about 6 h, but long enough for sensitization of 
tumors to the NQO1-bioactivatable drug + IR. Biomarker and DSB repair kinetics 
are ongoing in our laboratory in preparation for these radiosensitization studies.
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